Almirall S.A. (ALM)
Madrid Exchange · Spain · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 10.36 |
|---|---|
| 52-week range | 9.81 – 13.98 |
| Return, 1 month / 3 months | −0.4% / −6.3% |
| Return, 1 year / 3 years | −14.4% / +21.5% |
| Trend | Below its 200-day average |
| RSI (14) | 53 |
| Volatility (1 year) | 24.2% |
| Worst drawdown (1 year) | -27.9% |
| Average daily value traded | 1.29M EUR |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Almirall is a pharmaceutical company based in Barcelona, Spain, that concentrates on skin health. It develops and markets prescription medicines and medical aesthetic products used by dermatologists and other healthcare professionals, addressing conditions such as psoriasis, acne and other inflammatory skin disorders. The company also offers treatments in areas including respiratory and gastrointestinal medicine, serving patients and clinicians across Europe and other markets through its own sales teams and partnerships.
On this site Almirall S.A. appears as a stock on the Madrid Exchange (Spain), code ALM, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Almirall S.A. (ALM) trades on the Madrid Exchange in Spain. It last closed at EUR 10.36 on 23 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 173 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 14.4% and over the last three months it fell 6.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 25 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -9.5% | ||
| From 52-week high | -25.0% | ||
| Momentum | 26 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.3% | ||
| 6-month return | -18.2% | ||
| 12-month return, skipping the last month | -14.1% | ||
| Stability (higher is calmer) | 43 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.9% | ||
| Liquidity | 78 · Strong | Trades actively. | |
| Average daily value traded | 1.29M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 32 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.4% |
|---|---|
| 1 month | −0.4% |
| 3 months | −6.3% |
| 6 months | −18.2% |
| 1 year | −14.4% |
| 3 years | +21.5% |
| 5 years | −12.1% |
Signals
| 50-day / 200-day average | 10.33 / 11.45 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.23 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 0.1515 |
| 15 May 2025 | EUR 0.1490 |
| 17 May 2024 | EUR 0.1490 |
| 12 May 2023 | EUR 0.1490 |
| 13 May 2022 | EUR 0.1507 |
| 14 May 2021 | EUR 0.1499 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.